American Society of Hematology

The Hematologist: ASH News and Reports, the Society's member newsletter, is designed for the broad constituency of ASH, all working toward the ultimate goal of conquering blood diseases. The Hematologist updates readers about important developments in the field of hematology and highlights what ASH is doing for its members.

banner image

The Evolutionary Trajectory from Diagnosis to Relapse in Pediatric ALL

Dr. Raetz studies the trajectory of clonal emergence from diagnosis to relapse in childhood ALL.

Read more
banner image

Podcast: Perioperative Bridging is Falling Down

Drs. Cuker and Ortel discuss the BRIDGE trial and current relevance of perioperative bridging to treat patients.

Read more
banner image

DUSP4: New Tumor Suppressor in BCL With Some Very Druggable Targets

Dr. Johnson looks at DUSP4 as a new tumor suppressor in B-cell lymphoma.

Read more
View All

Presidents Column

Dr_ David A_ Williams - Presidents Column

David A. Williams, MD

Chief of Hematology/Oncology; Director of Clinical and Translational Research, Boston Children's Hospital, Boston, Massachusetts
Making Sense of New Drug Discovery
August 10, 2015

Dr. Williams highlights the many resources ASH provides to strengthen the field's research and drug discovery efforts.

View All

Clinical Trials Corner

CAR T Cells in Refractory Diffuse Large B-cell Lymphoma
August 12, 2015

Dr. LaCasce discusses a study that evaluates CAR T-cell therapy as a promising novel approach in patients with refractory aggressive B-cell lymphoma.

View All

Ask The Hematologist

Ask the Hematologist: Diagnosis of Immune Pathophysiology in Patients with Low-Risk Myelodysplastic Syndromes
August 14, 2015

Dr. Nakao discusses his approach to the diagnosis and treatment of immune pathophysiology in patients with low-risk myelodysplastic syndrome (MDS).

View All

Mini Review

New Clinical and Research Directions in Myeloma-Related Bone Disease
August 13, 2015

Dr. Raje and Dr. Santo discuss new insights into MM-related bone biology and potential novel therapeutic approaches for treating bone disease.

View All


ASH Minority Recruitment Initiative
September 2, 2015

The 2015 MMSAP/MRI winners discuss their research and mentor experience.

View All
  • NIH Identifies Priorities for Pediatric Therapeutics

    In compliance with the Best Pharmaceuticals for Children Act (BPCA), NIH published a list of therapeutics identified by the agency as the highest priority for study in pediatric populations. The BPCA requires sponsors of drugs for adult indications to study pediatric indications if a disease occurs in children. NIH must update its priority list every three years.

  • NHLBI Releases Draft Strategic Research Priorities for Review and Comments

    The National Heart, Lung and Blood Institute (NHLBI) released its draft strategic research priorities and is requesting additional input from the scientific community by August 28, 2015. The strategic planning process aims to identify compelling questions and critical challenges that should be addressed within the next decade.  ASH submitted several research recommendations based on the ASH Agenda for Hematology Research and ASH Sickle Cell Priorities and is pleased to see many of them incorporated into the NHLBI's draft strategic research priorities. All ASH members are encouraged to review and comment by the deadline.  Please see link above for more details.

  • Medicare Releases Proposed Payment Rates and Associated Policies for Physicians in 2016

    On July 8, 2015, the Centers for Medicare and Medicaid Services (CMS) released its proposed rule  governing payments for physician services and other associated policies covering the calendar year of 2016.  This is the first physician fee schedule proposed rule following the passage of the Medicare Access and CHIP Reauthorization Act (MACRA), which eliminated the sustainable growth rate formula that had long mandated cuts each year.  Please follow the link above to learn more.

  • Let ASH Know About Difficulties in Obtaining Guaranteed Coverage for Clinical Trials

    Guaranteeing access to clinical trials for cancer patients has long been a priority for ASH.  Recently, the Departments of Health and Human Services and Labor (which are both responsible for implementing the various provisions of the health reform law) announced there would not be federal regulations to implement the clinical trials coverage provision of the health reform law.  The agencies determined the statutory language was self-implementing, and indicated that the Departments do not expect to issue regulations in the near future.  Please follow the link above to learn more about this issue.

View all policy news
back to top